Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this crowded field comes a new player ... approval in 2022; the company filed ...

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...

The latest glucagon-like peptide 1 (GLP-1) receptor agonists have been heralded for their potential to not only boost weight loss and glucose ... tirzepatide, and new GLP-1 drugs in the research ...

Weight loss drugs catapulted many into a new wellness era, and gave hope to those with diabetes, obesity and who struggled to lose weight. The global anti-obesity drugs market — including the ...